louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02107794: Shared Decision Making in Graves Disease - Graves Disease (GD) Choice
Official title: Shared Decision Making in Graves Disease - Graves Disease (GD) Choice
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Graves' Disease
Thyroid Disease
Hyperthyroidism
Keywords: Grave's
Disease
Thyroid
Hyperthyroidism
Thyroidectomy
Radioactive
Iodine
Antithyroid
Shared
Decision
Making
Aid
Evidence
Based
Endocrinology
Mayo
Clinic
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2014-04-08
Enrollment: 93
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The investigators' decision aid for patients with GD, GD Choice, will be the result of a user-centered participatory action research involving) synthesis of the best available evidence from the literature and real-world registry experience, ii) input and involvement of patients, clinicians and other stakeholders, iii) direct observation of encounters and iv) extensive field-testing. The goal is to create a decision aid that will be rigorously evidence-based, clear and complete, able to be used by clinicians with minimal training time, while satisfying extant standards for rigorous high-quality shared decision making tools.


Eligibility criteria: Inclusion Criteria:

* Adults ≥ 18 years
* Diagnosis of Graves Disease
* Appointment with endocrinologist to discuss treatment options for Graves Disease

Exclusion Criteria:

* Major barriers to participate in shared decision making or to providing informed consent (i.e. dementia, severe hearing or visual impairment)

Primary outcomes:
measure: Decisional Quality (Knowledge, Decisional Conflict, Satisfaction) of 100 participants
timeFrame: up to 2 weeks post-visit
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Victor M Montori, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Brito JP, Castaneda-Guarderas A, Gionfriddo MR, Ospina NS, Maraka S, Dean DS, Castro MR, Fatourechi V, Gharib H, Stan MN, Branda ME, Bahn RS, Montori VM. Development and Pilot Testing of an Encounter Tool for Shared Decision Making About the Treatment of Graves' Disease. Thyroid. 2015 Nov;25(11):1191-8. doi: 10.1089/thy.2015.0277. Epub 2015 Oct 15.
Clinical trial NCT02499094: Modeling and Predicting Real World Behavior Using Mobile Sensor Data on Patients With Major Depressive Disorder
Official title: Modeling and Predicting Real World Behavior Using Mobile Sensor Data on Patients With Major Depressive Disorder: Protocol for a Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depressive Disorder
Lead sponsor: Ginger.io
Sponsor class: INDUSTRY
First posted: 2015-07-15
Enrollment: 1004
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to validate the effectiveness of using an integrated mobile sensing platform to deliver large-scale data-driven interventions to patients with depression.

Detailed description: This study is a smartphone-based, randomized, single-blind, controlled parallel-

design study with two intervention arms and one control arm. The two intervention arms

will receive in-app messages and phone-based support, which will be triggered by

participant's self-reported surveys and passive behavioral data gathered through a

smartphone app. The study will include a nationwide sample of adult (18 years or older)

smartphone users, who are currently experiencing depressive symptoms. The primary

outcome will be decrease in depression symptom severity, as measured by the 9-item

Patient Health Questionnaire, over 6 months.

Eligibility criteria: Inclusion Criteria:

* Currently suffering from depression (as measured by a PHQ-9 score of 10 or more at the time of screening)
* Own an iPhone or Android smartphone with a mobile voice calling plan with a US carrier
* Fluency in English

Exclusion Criteria:

* Participants with visual or hearing impairment
* Recent history of pregnancy (currently pregnant or those who have given birth within the past four months at the time of screening)
* Recent loss of a loved one (within the past two months at the time of screening)
* Unable or unwilling to accept End User License Agreement, or to provide information regarding their demographic characteristics and mental health history

Primary outcomes:
measure: Change in depression symptom severity
timeFrame: 6 months
Secondary outcomes:
measure: Change in patient activation
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04376294: Using of Extracorporeal Shockwave Therapy in Treatment Of Achilles Tendinopathy
Official title: Using of Extracorporeal Shockwave Therapy in Treatment Of Achilles Tendinopathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Achilles Tendinopathy
Lead sponsor: Cairo University
Sponsor class: OTHER
Collaborators: name: Prof.Dr. Emad Samuel Boles Saweeres
name: Prof.Dr Nadia Abdelazim fayaz
name: Mr.Mohamed Nasser Kise Helmy
First posted: 2020-05-06
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to determine the effect of extracorporeal Shock wave therapy (ESWT) on functional activity and pain in patients with Achilles tendinopathy

Detailed description: Fifty patients of both sexes with Achilles tendinopathy aged 18-40 years, were assigned randomly into two equal groups. The study group received ESWT in addition to a conservative physical therapy program for four weeks, while the control group received a conservative physical therapy program only. Pain and functional mobility were assessed before and after treatment through a visual analog scale (VAS) and Victorian Institute of sports assessment - Achilles questionnaire (VISA-A), respectively

Eligibility criteria: Inclusion criteria

* Clinical history of Achilles tendon pain for at least six months
* A minimum of three months conservative treatment administered without benefit for at least four weeks before ESWT.

Exclusion Criteria:

* Patients underwent physical therapy in the four weeks prior enrollment to study.
* Patients had taken non-steroidal anti-inflammatory medication during the previous week
* Patients had received peritendinous injections of a local anesthetic or corticosteroid within last 4 weeks
* Patients had bilateral Achilles tendinopathy
* Patients with other conditions that could significantly contribute to posterior ankle pain (osteoarthritis, radiculopathy, systemic neurologic conditions)
* Patients having previous injury or surgical treatments of the ankle.

Primary outcomes:
measure: The Victorian Institute of Sport Assessment-Achilles questionnaire (VISA-A).
timeFrame: 15 minutes
Secondary outcomes:
measure: The visual analog scale (VAS).
timeFrame: 15 minutes
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Cairo university
Study officials:
affiliation: Cairo University
name: Dr. Nasr A. Abdelkader, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06439394: An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
Official title: Patient Experience Study Evaluating Effect of OM3 on Dry Eye Symptoms and Quality of Life in Patients With Mild to Moderate Dry Eye Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dry Eye
Keywords: Dry Eye
OM3
Optive MEGA-3
AGN-OMEGA3
Lead sponsor: AbbVie
Sponsor class: INDUSTRY
First posted: 2024-06-03
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult participants with dry eye disease who are eligible based on the inclusion and exclusion criteria.

Brief summary: Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication. This study will evaluate real-world experiences with Optive MEGA-3 (OM3) on relieving dry eye symptoms in adult participants with DED.

OM3 is an over the counter (OTC) monograph drug indicated for the temporary relief of symptoms of eye dryness. Participants will administer 1 drop of OM3 on Day 1 for the acute phase of the study, then participants will administer 1-2 eye drops in each eye at least twice a day but as much as needed through Day 15. Around 50 adult participants will be enrolled at one site in the United States.

There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site as per standard of care.


Eligibility criteria: Inclusion Criteria:

* During a routine visit, investigator will decide whether artificial tears are the appropriate treatment for potential participants with dry eyes and will then consider enrollment into this study.
* Participant has at least one of the following signs of dry eye:

  * Three consecutive tear break-up time (TBUT) tests \<= 10 seconds in at least one eye at Screening Visit OR;
  * Grade 1 to 4 (modified National Eye Institute \[NEI\] Grid, score range = 0 to 5) staining in at least 1 area of the cornea (5 areas examined) or conjunctiva (6 areas examined) that is related to dry eye in at least 1 eye at Screening Visit.

Exclusion Criteria:

* Use of artificial tears in the last 24 hours.
* Use of more than 4 drops of artificial tears per day in each eye.
* Use of dry eye treatment other than artificial tears.

Primary outcomes:
measure: Acute Phase: Change from Baseline in Current Symptom Scores
timeFrame: Day 1; Hour 8
measure: Chronic Phase: Change from Baseline in Ocular Surface Disease Index (OSDI) Score
timeFrame: Day 15
Secondary outcomes:
Other outcomes:
Locations:
city: Memphis
country: United States
facility: Southern College of Optometry /ID# 262668
state: Tennessee
Study officials:
affiliation: AbbVie
name: ABBVIE INC.
role: STUDY_DIRECTOR
References:
Clinical trial NCT01758094: Plasma RBP Levels in Patients With Idiopathic Hypogonadotrophic Hypogonadism
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Idiopathic Hypogonadotropic Hypogonadism
Keywords: hypogonadism
Retinol binding globulin 4
Testosterone treatment
Lead sponsor: Gulhane School of Medicine
Sponsor class: OTHER
First posted: 2013-01-01
Enrollment: 25
Sex: MALE
Minimum age (years): 19
Maximum age (years): 26
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with hypogonadotrophic hypogonadism

Brief summary: The aim of the present study was to demonstrate the RBP4 levels, association of RBP4 with insulin resistance and influence of testosterone treatment on this cytokine in patients with idiopathic hypogonadotropic hypogonadism.


Eligibility criteria: Inclusion Criteria:

decreased serum testosterone concentration below the normal range (serum T \< 300ng/dL), FSH and LH levels within or below the normal range, absence of a pituitary or hypothalamic mass lesions on MRI, presence of gonadotropin response to repetitive doses of GnRH, normal smell test and normal karyotypes

Exclusion Criteria:

previous androgen treatment, history of smoking, presence of bilateral anorchia, intellectual deficiency, diabetes mellitus, arterial hypertension or dyslipoproteinemia, medication of any kind and drug abuse. Because of possible confounding effects, patients with other hormone deficiencies were excluded.

-

Primary outcomes:
measure: Retinol binding protein 4, hs-CRP levels in patients with idiopathic hypogonadotrophic hypogonadism
timeFrame: 2008-2012
Secondary outcomes:
measure: Effect of testosterone treatment on retinol binding globulin 4 and hs-CRP levels in patients with hypogodotrophic hypogonadism
timeFrame: 2008-2012
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Gulhane School of Medicine Dep. of Endocrinology and Metabolism
Study officials:
affiliation: Gulhane School of Medicine, Department of Endocrinology and Metabolism
name: Aydogan Aydogdu, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02625194: The Utility of Oxygen Insufflation During Flexible Fiberoptic Bronchoscope-guided Intubation
Official title: The Utility of Oxygen Insufflation During Flexible Fiberoptic Bronchoscope-guided Intubation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lumbar Spinal Stenosis
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2015-12-09
Enrollment: 36
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study investigate the utility of continuous oxygen insufflation during fiberoptic bronchoscope-guided intubation.

One group receives oxygen via suction channel of fiberoptic bronchoscope during intubation.

The other group does not receive oxygen during fiberoptic bronchoscope-guided intubation.

Then, the velocity of deoxygenation difference of PaO2(baseline

Detailed description: Fiberoptic bronchoscope-guided intubation is a gold standard for intubation of a patient with anticipating difficult airway. This technique takes several minutes without oxygen supply, which results in hypoxia when it prolonged. If continuous supply of oxygen during procedure improve the oxygenation, we can reduce the risk of hypoxemia and increase the safety margin during procedure.

Eligibility criteria: Inclusion Criteria:

* patients who have surgery under general oral endotracheal anesthesia with invasive arterial blood pressure monitoring

Exclusion Criteria:

* history of lung disease
* abnormality in chest x-ray
* anticipating difficult intubation
* pregnant women
* who is unable to understand and agree the consent form

Primary outcomes:
measure: Velocity of PaO2 decrease
timeFrame: from mask removal to 1st manual ventilation after intubation, up to 5 minute
Secondary outcomes:
measure: success of intubation
timeFrame: 300 sec after the beginning of intubation
measure: PaO2
timeFrame: 1. 5 minutes after manual ventilation / 2.right before 1st manual ventilation after intubation, up to 5 minute
measure: PaCO2
timeFrame: 1. 5 minutes after manual ventilation / 2.right before 1st manual ventilation after intubation, up to 5 minute
measure: pH
timeFrame: 1. 5 minutes after manual ventilation / 2.right before 1st manual ventilation after intubation, up to 5 minute
measure: visual field
timeFrame: throughout the intubation with bronchoscope, upto 5 minute
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Gangnam severance hospital
Study officials:
affiliation: Yonsei University Gangnam Severance Hospital
name: Jeong Soo Lee, MD
role: STUDY_CHAIR
References:
citation: Roh GU, Kang JG, Han JY, Chang CH. Utility of oxygen insufflation through working channel during fiberoptic intubation in apneic patients: a prospective randomized controlled study. BMC Anesthesiol. 2020 Nov 10;20(1):282. doi: 10.1186/s12871-020-01201-9.
Clinical trial NCT01123694: Xeroderma Pigmentosum Patient Experiences
Official title: Xeroderma Pigmentosum: A Survey of Patient Experiences
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Xeroderma Pigmentosum
Keywords: xeroderma pigmentosum
quality of life
DLQI
CDLQI
Lead sponsor: Henry Ford Health System
Sponsor class: OTHER
First posted: 2010-05-14
Enrollment: 15
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study population will be a convenience sample of XP patients from Camp Sundown, a camp for children with XP.

Brief summary: Xeroderma Pigmentosum (XP) is a rare skin condition that causes extreme sensitivity to the sun and an increased incidence of skin cancers. The purpose of this study is to find out more about XP patient experiences and their quality of life.


Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of xeroderma pigmentosum
* Any age
* Access to a public or private computer

Exclusion Criteria:

* Patients who do not have a confirmed diagnosis of XP
* Patients under 18 who do not have a parent/guardian able to read or speak English
* Patients who are unable to read or speak English

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Detroit
country: United States
facility: Henry Ford Medical Center, New Center One
state: Michigan
Study officials:
affiliation: Henry Ford Hospital Department of Dermatology
name: Henry W Lim, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05590494: Novel Treatment for Rotator Cuff Tears
Official title: Ultrasonic Tenotomy as a Treatment of Partial Rotator Cuff Tear of the Supraspinatus Tendon: A Pilot Feasibility Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Supraspinatus Tear
Keywords: Ultrasonic tenotomy
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2022-10-21
Enrollment: 15
Sex: ALL
Minimum age (years): 25
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The focus of this study is to examine changes in pain scores, strength, and range of motion over time following an ultrasonic tenotomy on a partial tear (\<50%) of the supraspinatus tendon of the rotator cuff.


Eligibility criteria: Inclusion Criteria:

- Evidence of partial tear (\< 50%) of the supraspinatus tendon on MRI.

Exclusion Criteria:

* A tear of the supraspinatus tendon greater \> 50% and any areas of full thickness tearing, concomitant tears \> 25% of other rotator cuff tendons (infraspinatus, teres minor or subscapularis), or acute tear of the glenoid labrum.
* Evidence of systemic illness/infection requiring oral or IV antibiotics during the recruitment period.
* Evidence of overlying skin infection or lesion at the proposed device insertion point on the shoulder.
* Previous corticosteroid injection within three months.
* Those individuals less than 25 and greater than 75 years of age will be excluded.

Primary outcomes:
measure: Change in pain
timeFrame: Baseline, 2, 6, 12 and 24-weeks post-procedure
measure: Change in shoulder active range of motion
timeFrame: Baseline, 2, 6, 12 and 24-weeks post-procedure
measure: Change in shoulder strength
timeFrame: Baseline, 2, 6, 12 and 24-weeks post-procedure
Secondary outcomes:
measure: Change in quality of life
timeFrame: Baseline, 2, 6, 12 and 24-weeks post-procedure
Other outcomes:
Locations:
city: Onalaska
country: United States
facility: Mayo Clinic Health System - Onalaska
state: Wisconsin
Study officials:
affiliation: Mayo Clinic
name: Jacob Erickson, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06764394: The Effect of Myofascial Release Exercises on Viscoelastic Changes of the Pectoralis Major Muscle, Pain, Range of Motion and Shoulder Functionality in Individuals Receiving Adjuvant Radiotherapy After Breast Cancer Surgery
Official title: The Effect of Myofascial Release Exercises on Viscoelastic Changes of the Pectoralis Major Muscle
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Breast Cancer
Keywords: myofascial release exercises, breast cancer, radiotherapy
Lead sponsor: Acibadem University
Sponsor class: OTHER
First posted: 2025-01-08
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Chemotherapy, hormone therapy and radiotherapy used in the treatment of breast cancer try to prevent the recurrence of cancer. In addition to the benefits of radiotherapy, such as a decrease in recurrence and an increase in long-term survival, it may have side effects that may affect the well-being and daily life activities of patients. One of the treatment modalities used to cope with treatment-related side effects is myofascial release exercises. Myofascial release exercises can help reduce adhesions caused by scar tissue and fibrosis caused by radiation. In the literature, there is no study investigating the effect of myofascial release exercises on pectoralis major muscle viscoelastic structure. For this purpose, our study aims to investigate the effect of myofascial release exercises performed in addition to home exercise programme on pectoralis major muscle viscoelastic structure, pain, range of motion and shoulder functionality.


Eligibility criteria: Inclusion Criteria:

* -Stage I-II-III defined by radiation oncologists after breast cancer surgery and who will start radiotherapy
* Breast conserving surgery or total mastectomy with axillary lymph node dissection during surgery
* No neurological or orthopaedic problems that may limit the range of motion of the shoulder joint in the preoperative evaluations,
* Individuals who volunteer to participate in the study will be included.

Exclusion Criteria:

* Previous breast clamp surgery on the same side or contralateral side,
* With a metastatic cancer focus,
* Post-surgical resistance, infection and open wound, pacemaker,
* Patients with a Mini Mental State Examination test score of less than 21 will be excluded from the study.

Primary outcomes:
measure: Tone - pectoralis major
timeFrame: 6 weeks
measure: Range of motion
timeFrame: 6 weeks
Secondary outcomes:
measure: Pain - Visual Analogue Scale
timeFrame: 6 weeks
measure: Shoulder Pain and Disability Index- SPADI
timeFrame: 6 weeks
measure: Quality of Life- Functional Assessment of Cancer Therapy-Breast" (FACT-B)
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: SBU. Prof. Dr. Cemil Taşçıoğlu City Hospital- Oncology Clinic
Study officials:
References: